L’associazione A.M.I.C.A. ci segnala l’importante
studio scientifico condotto dal prof. Dominique Belpomme da poco pubblicato ,
dove vengono definiti i biomarkers diagnostici che identificano l’elettrosensibilità
come malattia.
Il professore insieme ad altri scienziati
si è fatto portavoce di una petizione rivolta all’Organizzazione Mondiale per
la Sanità per richiedere il riconoscimento della MCS e della Elettrosensibilità
nella Classificazione Internazionale delle Malattie.
Clicca QUI per firmare la petizione ( in
inglese ) :
---o---o---o---o---o---o---o---o---o---
Rev
Environ Health. 2015 Dec 1;30(4):251-71. doi:
10.1515/reveh-2015-0027.
Reliable disease biomarkers characterizing and
identifying electrohypersensitivity and multiple chemical sensitivity as two
etiopathogenic aspects of a unique pathological disorder.
Abstract
Much
of the controversy over the causes of electro-hypersensitivity (EHS) and
multiple chemical sensitivity (MCS) lies in the absence of both recognized
clinical criteria and objective biomarkers for widely accepted diagnosis. Since
2009, we have prospectively investigated, clinically and biologically, 1216
consecutive EHS and/or MCS-self reporting cases, in an attempt to answer both
questions. We report here our preliminary data, based on 727 evaluable of 839
enrolled cases: 521 (71.6%) were diagnosed with EHS, 52 (7.2%) with MCS, and
154 (21.2%) with both EHS and MCS. Two out of three patients with EHS and/or
MCS were female; mean age (years) was 47. As inflammation appears to be a key
process resulting from electromagnetic field (EMF) and/or chemical effects on
tissues, and histamine release is potentially a major mediator of inflammation,
we systematically measured histamine in the blood of patients. Near 40% had a
increase in histaminemia (especially when both conditions were present), indicating
a chronic inflammatory response can be detected in these patients. Oxidative
stress is part of inflammation and is a key contributor to damage and response.
Nitrotyrosin, a marker of both peroxynitrite (ONOO°-) production and opening of
the blood-brain barrier (BBB), was increased in 28% the cases. Protein S100B,
another marker of BBB opening was increased in 15%. Circulating autoantibodies
against O-myelin were detected in 23%, indicating EHS and MCS may be associated
with autoimmune response. Confirming animal experiments showing the increase of
Hsp27 and/or Hsp70 chaperone proteins under the influence of EMF, we found
increased Hsp27 and/or Hsp70 in 33% of the patients. As most patients reported
chronic insomnia and fatigue, we determined the 24 h urine 6-hydroxymelatonin
sulfate (6-OHMS)/creatinin ratio and found it was decreased (<0.8) in all
investigated cases. Finally, considering the self-reported symptoms of EHS and
MCS, we serially measured the brain blood flow (BBF) in the temporal lobes of
each case with pulsed cerebral ultrasound computed tomosphygmography. Both
disorders were associated with hypoperfusion in the capsulothalamic area,
suggesting that the inflammatory process involve the limbic system and the
thalamus. Our data strongly suggest that EHS and MCS can be objectively
characterized and routinely diagnosed by commercially available simple tests.
Both disorders appear to involve inflammation-related hyper-histaminemia,
oxidative stress, autoimmune response, capsulothalamic hypoperfusion and BBB
opening, and a deficit in melatonin metabolic availability; suggesting a risk
of chronic neurodegenerative disease. Finally the common co-occurrence of EHS
and MCS strongly suggests a common pathological mechanism.
FONTE : The National Center for Biotechnology Information
